Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597227 | 0.95 | USP30 (0.42) | FPR2HDAC6HDAC4USP30IDO1 | |
| SCHEMBL5597160 | 0.89 | GPR119 (0.41) | FPR2USP30IDO1TDO2GPR119 | |
| SCHEMBL5596980 | 0.85 | USP30 (0.42) | FPR2CYP2C9HDAC6HDAC4USP30 | |
| SCHEMBL5597012 | 0.82 | FPR2 (0.44) | FPR2CYP2C9HDAC6HDAC4USP30 | |
| SCHEMBL5596376 | 0.82 | FPR2 (0.44) | FPR2CYP2C9HDAC6HDAC4USP30 | |
| SCHEMBL5596878 | 0.80 | USP30 (0.47) | USP30GPR119PIK3R1PIK3CAPRMT5 | |
| SCHEMBL5597039 | 0.79 | FPR2 (0.41) | FPR2CYP2C9HDAC6HDAC4USP30 | |
| SCHEMBL5596817 | 0.78 | GPR119 (0.43) | FPR2IDO1TDO2GPR119 | |
| SCHEMBL5596601 | 0.76 | USP30 (0.42) | FPR2HDAC6HDAC4USP30GPR119 | |
| SCHEMBL5596990 | 0.76 | USP30 (0.40) | FPR2USP30IDO1TDO2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | FPR2 3865/4885CYP2C9 3893/4885HDAC6 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.